A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
暂无分享,去创建一个
D. Majumdar | C. Beattie | K. Christov | T. K. Das Gupta | J. Richards | T. Yamada | M. Warso | D. Mehta | C. Schaeffer | S. Kennedy | L. Rae Bressler